BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Molecular Staging Inc. Announces Appointment Of Dr. Richard Barker As Executive Chairman Of The Company's Board Of Directors


10/19/2005 5:09:44 PM

NEW HAVEN, Conn.--(BUSINESS WIRE)--Jan. 20, 2004--Molecular Staging Inc. (MSI) today announced the appointment of Dr. Richard Barker as Executive Chairman of the company's Board of Directors. Dr. Barker has had more than 20 years experience in senior leadership roles in the health care industry. Dr. Barker's previous roles include CEO of Chiron Diagnostics, a $600 million division of the biotechnology company Chiron, developing and marketing diagnostic systems worldwide. Prior to that, he was the first General Manager of IBM's $2 billion worldwide health care solutions business. Dr. Barker also spent 13 years with McKinsey & Company leading that firm's pharmaceutical practice in Europe. Dr. Barker has a D.Phil. in Biophysics and a BA in Chemistry, both from Oxford.

"We are delighted that Richard has accepted the invitation to join our board in the role of Executive Chairman," said Jim Blair, a member of MSI's Board of Directors, and General Partner of Domain Associates, one of MSI's original investors. "Richard's extensive experience in the health care industry across pharmaceuticals and diagnostics will be invaluable as we expand and leverage our leadership positions in both proteomic biomarker discovery and whole genome amplification."

Molecular Staging Inc. (MSI) has developed a range of transformational products and services based on its advanced amplification technologies. These products and services include an integrated proteomics chip based discovery service which offers a powerful new way to identify individual and multiplexed sets of protein biomarkers to enable faster development of more effectively targeted drugs and diagnostics. MSI has also developed REPLI-g whole genome amplification kits and services, a rapid, reliable method of generating unlimited DNA from a few cells to address DNA constraints arising from the rapid growth in volume and variety of genetic tests. Additional information about MSI can be found at www.molecularstaging.com.

Contact:

Molecular Staging Jennifer Joiner, 203-772-5000

Source: Molecular Staging Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES